Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FEMSTAT 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FEMSTAT 3.
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER vs FEMSTAT 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death. At high concentrations, it may also directly damage fungal membranes.
Butoconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity.
200 mg IV loading dose, then 100-200 mg IV once daily; for invasive candidiasis, 800 mg IV loading dose then 400 mg IV once daily.
Intravaginal cream: 1 applicatorful (5 g of 2% butoconazole nitrate) intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function; prolonged to 98 hours in end-stage renal disease, requiring dose adjustment.
The terminal elimination half-life of butoconazole following topical vaginal administration is approximately 21-24 hours. This prolonged half-life supports once-daily dosing for 3 days in the treatment of vulvovaginal candidiasis.
Approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 11% is excreted as metabolites in urine; fecal excretion accounts for less than 5%.
Following topical vaginal administration of butoconazole nitrate, approximately 5% of the dose is absorbed systemically. The absorbed fraction is primarily metabolized in the liver and excreted via the biliary/fecal route. Renal excretion accounts for less than 3% of the administered dose.
Category C
Category C
Antifungal
Antifungal